TX-MARY-KAY
22.12.2022 17:06:37 CET | Business Wire | Press release
Mary Kay recently announced its sustainability strategy – Enriching Lives Today for a Sustainable Tomorrow – which encompasses five pillars, 15 commitments, and over a decade of action. This strategy was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay an essential part of a global coalition to ensure a better future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005031/en/
Mary Kay Inc. partners with local and global organizations to further their mission to enrich women’s lives and bring education opportunities to young women around the world.
As part of this overarching strategy and to continue its decades-long advocacy for women’s empowerment, education and entrepreneurship, Mary Kay is committed to providing 250,000 young women education opportunities by 2030. To further its mission of enriching women’s lives, partnerships and scholarships with local and global organizations in 2022 ensured young women around the world are provided with exceptional education opportunities to pursue their dreams.
2022 Mary Kay Inc. Partnerships/Programs included:
- Young Women in STEAM Grants – Six recipients received grants created to elevate young women in STEAM fields and encourage them to continue their passions and career pursuits. The 2022 recipients were from N. Macedonia, Germany, the Philippines, China, and Australia pursuing careers in everything from app development and architecture to physics and geothermal inventions.
- Young Women in STEAM Continuing Education Grant – As an extension of Mary Kay’s Young Women in STEAM grants and social campaign, Ivanna Hernandez, a 2021 grant recipient, was awarded a second grant to help further pursue her dream of becoming the first Latin American woman astronaut to go to Mars. She was featured in a documentary created to inspire young women to shoot for the stars – or Mars in this case!
- Society of Cosmetic Chemists Madam C. J. Walker Scholarship – Established to honor Walker, the first female, self-made millionaire who made her fortune by developing a line of cosmetics and hair care products for Black women. At the SCC 75th Annual meeting, Ms. A’Lelia Bundles, the great-great-granddaughter of Madam C.J. Walker, and Michelle Hines, Ph.D., Director of Product Formulation at Mary Kay, presented the Madam C. J. Walker Scholarships for under-represented minority students pursuing higher education in STEM disciplines related to the cosmetics and personal care industry. The award is supported by the Society of Cosmetic Chemists and partnered and funded by Mary Kay. The winning recipients included: Joy Rutherford, fifth-year PhD student and NIH Research Fellow; and Imani Elaine Porter, Hampton University, second-year undergraduate in biochemistry.
- Network for Teaching Entrepreneurship – Partnering to provide 47,000 youth globally with entrepreneurship curriculum and innovative thinking opportunities. Through support of 1) the Aspiring Entrepreneurs Program (U.S.) core program; 2) World Series of Innovation; and 3) World Series of Innovation Challenge Innovation Days, Mary Kay is helping to empower youth to reach their entrepreneurial dreams. In the 2021-2022 school year, Mary Kay sponsored the NFTE World Series of Innovation (WSI) where 21 teams of emerging social entrepreneurs won a total of $16,800 for their proposed solutions to seven challenges, each of which focused on advancing a Sustainable Development Goal. Sponsors of the seven innovation challenges included: Bank of the West, Citi Foundation, Mary Kay, Saint-Gobain North America, Ernst & Young, LLP (EY), Maxar Technologies, and PIMCO. The 2022 World Series of Innovation Challenge launched in September 2022 and Mary Kay is participating for a third year tackling SDG 14: Life Below Water.
- City of Lewisville, IncubatorEDU – In partnership with the Lewisville Independent School District (LISD), IncubatorEDU offers a robust entrepreneurship curriculum to Lewisville High School students. Community mentors and an end-of-year pitch event provide the students with real-life entrepreneurial experience and education opportunities.
- Academy of Marketing Science – For more than 25 years, Mary Kay has supported the Mary Kay Dissertation and Dissertation Proposal Awards at the annual Academy of Marketing Science (AMS) conference where doctoral student participants showcase their successfully defended dissertations and receive a monetary award and critical peer feedback to improve their chances of publishing their work in academic journals in the future.
- Ursuline Academy of Dallas – Mary Kay Ash Endowed Scholarship – Scholarship awarded annually to support girls with an education that equips them with the skills and confidence needed to do great things.
- Army Scholarship Foundation - Mary Kay Corporation Honorary Scholarship – Scholarship awarded annually to deserving sons and daughters of US Army soldiers and Army veterans, and to spouses of enlisted active-duty soldiers.
- Hispanic Scholarship Fund – Scholarship awarded annually to support and empower students and parents with the knowledge and resources to successfully complete a higher education, while providing support services and scholarships to as many exceptional students, HSF scholars and Alumni as possible.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom